Clinical trials: Allogeneic Disease
Stem Cell Transplantation, Hematopoietic, Poor Graft Function
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor…
- Conditions
- Stem Cell Transplantation, Hematopoietic, Poor Graft Function, Delayed Platelet Engraftment, Hematological Diseases
- Trial name
- NCT02240992
- Testing
- PBSC, MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure high-risk MDS patients. At present, the best conditioning regimen for high-risk MDS patients undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT05453552
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Multiple System Atrophy, Parkinsonism
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
The prevalence of Multiple System Atrophy (MSA) is reported to be between 3.4 - 4.9 cases per 100,000 population. The estimated average incidence is 0.6 - 0.7 cases per 100,000 people per year.
- Conditions
- Multiple System Atrophy, Parkinsonism, Multiple System Atrophy, Parkinson Variant
- Trial name
- NCT04876326
- Testing
- Autologous Adipose Mesenchymal Stem Cell Implantation, Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation, Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- Universitas Indonesia
Hematologic Malignancies
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
This study will determine the Maximal Tolerated Dose if any and the recommended dose for phase 2 of monalizumab, a monoclonal antibody directed against the CD94/NKG2A receptor, after allogenic stem cell transplantation.
- Trial name
- PIRAT (NCT02921685)
- Testing
- Monalizumab
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut Paoli-Calmettes
B-cell Acute Lymphoblastic Leukemia
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
To explore the efficacy and safty of Blinatumomab as a bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05559450
- Testing
- Blinatumomab, Conventional therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Kidney Cancer
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00243009
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Graft-versus-host-disease, CMV
Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease
Explore the tolerability and efficacy of letermovir in the prevention of CMV reactivation in patients with acute and chronic graft-versus-host disease (GVHD) beyond day 100.
- Trial name
- NCT05969743
- Testing
- Letermovir
- Volunteers
- 42 people
- Sponsor
- Rabin Medical Center
Acute Lymphoid Leukemia
Donor-specific Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia (ALL)
[Study Objectives] To evaluate the efficacy of allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) in the first or second complete remission (CR).
- Trial name
- AHCTALL (NCT01037764)
- Testing
- alloHCT
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome
Reduce Immunosuppression With Atmp in NS ChildrEn
A phase II open-label, single arm study aimed to ascertain whether infusions of cord-blood mesenchymal stromal cells (CB-MSCs) allow to reduce or suspend the chronic immunosuppressive therapy (IS) in steroid-dependent nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome, Idiopathic Nephrotic Syndrome
- Trial name
- RACE (NCT04034316)
- Testing
- Cord-blood mesenchymal stromal cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Testicular Injury, Oligospermia
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Testicular Injury and Oligospermia
- Trial name
- NCT05158114
- Testing
- AlloRx
- Where
- Antigua and Barbuda
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Hematological Malignancies, Allogeneic Transplantation
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
In this study, treosulfan is evaluated for conditioning in allogenic stem cell transplantation. The procedure and the follow-up are the same as in standard allogenic transplant. The donor is unrelated (identical HLA).
- Trial name
- NCT00129155
- Testing
- treosulfan
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Cancer, Leukemia
Peer Support Group for Adolescent and Young Adult (AYA) Allogeneic Stem Cell Transplant Recipients
Allogeneic Haemopoietic Stem Cell Transplant (Allo-HSCT) is a potentially curative option for patients with both malignant and non-malignant hematological disorders.
- Conditions
- Cancer, Leukemia, Stem Cell Transplant
- Trial name
- NCT06704243
- Testing
- Peer Support
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Myelodysplastic Syndromes, Acute Leukemia
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
Multi-site, non-randomized Phase I/II study involving children and adults.
- Trial name
- NCT02752243
- Testing
- CIK-Cells
- Where
- 5 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Peter Bader
Acute Myeloid Leukemia, Allogeneic Haematopoietic Progenitor Cell Transplant
Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis
The trial is planned as a multicentric, national, phase II, open-label trial to evaluate safety and tolerance of nebulized Liposomal Amphotericin B (Ambisome) for LMA patients during the induction therapy ,intensification, plus…
- Trial name
- AMBINEB (NCT00391014)
- Testing
- liposomal Amphotericine B
- Where
- 4 sites in Spain
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Leukemia
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims of the study are to learn how safe GDX012 is, how treatment with GDX012 is tolerated and…
- Trial name
- NCT05886491
- Testing
- GDX012, Chemotherapy Agents
- Where
- 11 sites in United States, Japan
- Volunteers
- 16 people
- Sponsor
- Takeda
Glioblastoma, Glioblastoma Multiforme
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
The purpose of this study is to test the safety and effects of a special type of a cancer vaccine called a 'dendritic cell vaccine' in patients with either newly diagnosed or recurrent glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma
- Trial name
- NCT02010606
- Testing
- Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Cedars-Sinai Medical Center
Hematological Malignancies
Dose-range Finding Treosulfan-based Conditioning
Evaluation of the safety and efficacy of 3 x 10, 3 x 12 or 3 x 14 g/m² Treosulfan resp., combined with 5 x 30 mg/m² fludarabine prior to allogeneic, hematopoietic stem cell transplantation of patients with hematological…
- Trial name
- NCT01063647
- Testing
- Treosulfan
- Where
- 7 sites in Finland, Germany and 2 more
- Volunteers
- 56 people
- Sponsor
- medac GmbH
Hematologic Diseases, Stem Cell Transplantation
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
This study is designed to assess the hypothesis that the lipopolysaccharide (LPS) activity index can be quantified early after transplantation, as well as the the PhosphoLipid Transfer Protein (PLTP) activity and these both…
- Trial name
- MetAlloLip (NCT03918343)
- Testing
- Blood sample
- Where
- 2 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Non-Hodgkin Lymphoma
Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
To evaluate the use of ibritumomab tiuxetan (Zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from…
- Trial name
- Z-RIC-Allo (NCT00644371)
- Testing
- Ibritumomab Tiuxetan (Zevalin)
- Where
- 14 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Myeloid Malignancy, Bone Marrow Failure Syndrome
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
The purpose of this study is to find out what effects, good and/or bad, the addition of clofarabine, a new chemotherapy agent, to a standard busulfan and fludarabine conditioning treatment has.
- Conditions
- Myeloid Malignancy, Bone Marrow Failure Syndrome, Transfusion-dependent Red Blood Cell (RBC) Defect, Congenital Immunodeficiency
- Trial name
- NCT01596699
- Testing
- Alemtuzumab, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.